Elsevier

European Journal of Cancer

Volume 31, Issue 12, November 1995, Pages 1924-1927
European Journal of Cancer

Special paper
Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy?

https://doi.org/10.1016/0959-8049(95)00421-1Get rights and content

Abstract

At the EORTC NCI New Drug Development Meeting in Amsterdam in 1994, a workshop, suggested by the EC PET (positron emission tomography) Oncology concerted action, was held to bring together many of those European PET centres investigating the use of [18F]FDG ([18F]2-fluoro-2 deoxyglucose) PET scanning as a measure of response to cancer therapy. Of the current 31 PET centres in Europe invited to contribute, 15 centres already had data and others expressed interest. Many of the groups were collaborating with local oncologists to measure tumour response to chemotherapy (12 groups) and radiotherapy (three groups) with this technique. Despite variations of methodology, and difficulties in data interpretation, assessment of tumour [18F]FDG uptake was thought to be a reasonable method for the functional imaging of tumours, assessing metabolic rate and providing a measure of tumour response. Broadly, pooling experience, it would appear that changes in [18F]FDG tumour uptake following one or two cycles of chemotherapy treatment was related to ultimate clinical responses. Patients showing most reduction in [18F]FDG uptake achieved the best clinical responses. Data were also available on the effect of chemotherapy on normal tissues and some data on the effect of radiotherapy and tumour response. It was concluded that changes in [18F]FDG uptake as measured with PET may provide useful information on clinical as well as subclinical response of tumours to anticancer therapy. This could be useful as a guide to early response to therapy as well as providing functional assessment of residual masses of disease. More specific markers of cellular proliferation e.g. [11C]thymidine, or [11C]-amino acids may provide even more accurate information. A strategy was outlined whereby PET scanning protocols could parallel EORTC early clinical trials so that [18F]FDG response information could supplement phase I and II clinical studies. Following these developments, an EORTC study group was formed under the auspices of the EORTC research branch, and the strategy for future development in Europe outlined.

References (14)

  • BM Gallagher et al.

    Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F]2-deoxy-2-fluoro-D-glucose

    J Nucl Med

    (1978)
  • LG Strauss et al.

    The applications of PET in clinical oncology

    J Nucl Med

    (1991)
  • AA Mancuso et al.

    The promise of FDG in diagnosis and surveillance of head and neck cancer

    Cancer

    (1994)
  • R Bares et al.

    FDG-PET for metabolic classification of residual lymphoma masses after chemotherapy

    J Nucl Med

    (1994)
  • G DiChiro et al.

    Glucose utilisation of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography

    Neurology

    (1982)
  • S Leskinen-Kallio et al.

    Uptake of carbon-11-methionine and fluorodeoxyglucose in non Hodgkins's lymphoma: a PET study

    J Nucl Med

    (1991)
  • KA Kern et al.

    Metabolic imaging of human extremity musculoskeletal tumours by PET

    J Nucl Med

    (1988)
There are more references available in the full text version of this article.

Cited by (100)

  • A Role for PET/CT in Response Assessment of Malignant Pleural Mesothelioma

    2022, Seminars in Nuclear Medicine
    Citation Excerpt :

    This was considered with the adjustment that the point of best overall response (BOR) can be reached even after a previous exam that already showed a progressive disease (PD). 18F-fluorodeoxyglucose (FDG) uptake detected in positron emission tomography and/or computed tomography (PET/CT) enables response assessment sooner after starting a therapy compared to classical CT criteria like RECIST; declining uptake of the tumor lesions due to cancer cell death is often detectable before the corresponding anatomical change becomes measurable.38 There are two major response criteria designed for PET diagnostic in widespread use today: The EORTC criteria, named after the European Organization for Research and Treatment of Cancer (EORTC) PET study group, were published in 199939 and PET Response Criteria in Solid Tumors (PERCIST) proposed by Wahl et al. in 2009.40

  • Changes in cervical cancer FDG uptake during chemoradiation and association with response

    2013, International Journal of Radiation Oncology Biology Physics
    Citation Excerpt :

    This difference may be due to the timing of the PET scans during therapy or differences in pretreatment tumor volumes and SUVmax. Other studies have also suggested that FDG uptake decreases earlier than tumor shrinkage (16, 17). In previous research that included later during-treatment PET imaging, 6 cervical patients were observed to have a CMR during treatment (18).

  • PET and PET-CT Imaging in Treatment Monitoring of Breast Cancer

    2009, PET Clinics
    Citation Excerpt :

    This approach works well for some sites of metastatic disease, such as the liver and lungs, but regional nodal disease and bones are difficult to evaluate.55 These limitations of CT/MRI can be effectively overcome by functional imaging techniques, which have the unique ability to detect subclinical alterations in tumor physiology and biochemistry resulting from efficacious therapy.56 Besides this, 18F-FDG PET also identified patients with low tumor metabolic activity before treatment as not achieving histopathologic response, suggesting that breast cancers with low metabolic activity are not likely to respond to primary chemotherapy, thus guiding initial management.40–42,57

  • PET, PET/CT, and PET/MR Imaging Assessment of Breast Cancer

    2008, PET Clinics
    Citation Excerpt :

    The most important step in the evaluation of treatment response is the identification of nonresponders as early as possible after the initiation of chemotherapy so that expensive, ineffective, and toxic drugs can be discontinued and alternative treatment methods instituted. Limitations of CT and MR imaging can be overcome by functional imaging techniques that can detect subclinical alterations in tumor metabolism resulting from therapy.63 FDG PET has been used to assess the response of tumor during and after completion of treatment of breast cancer.64–66

View all citing articles on Scopus
View full text